Paul Trower - Net Worth and Insider Trading
Paul Trower Net Worth
The estimated net worth of Paul Trower is at least $2 Million dollars as of 2023-03-28. Paul Trower is the Principal Accounting Officer of Incyte Corp and owns about 21,734 shares of Incyte Corp (INCY) stock worth over $2 Million. Details can be seen in Paul Trower's Latest Holdings Summary section.
Transaction Summary of Paul Trower
Paul Trower Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul Trower owns 1 companies in total, including Incyte Corp (INCY) .
Click here to see the complete history of Paul Trower’s form 4 insider trades.
Insider Ownership Summary of Paul Trower
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2015-05-04 | VP & Finance & Prin Acc Officer |
Paul Trower Latest Holdings Summary
Paul Trower currently owns a total of 1 stock. Paul Trower owns 21,734 shares of Incyte Corp (INCY) as of June 23, 2020, with a value of $2 Million.
Latest Holdings of Paul Trower
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2020-06-23 | 21,734 | 70.31 | 1,528,118 |
Holding Weightings of Paul Trower
Paul Trower Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul Trower has made a total of 8 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 8 sells. The most-recent trade in Incyte Corp is the sale of 6,943 shares on June 23, 2020, which brought Paul Trower around $763,730.
Insider Trading History of Paul Trower
- 1
Paul Trower Trading Performance
Paul Trower Ownership Network
Ownership Network List of Paul Trower
Ownership Network Relation of Paul Trower
Paul Trower Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Paul Trower is the VP & Finance & Prin Acc Officer of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Paul Trower made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Paul Trower Mailing Address
Above is the net worth, insider trading, and ownership report for Paul Trower. You might contact Paul Trower via mailing address: 1801 Augustine Cut-off, Wilmington De 19803.
